Direct compression of Sulfadimoxine (SDM) 500 mg tablets begins with particle size control because the free acid crystalline fraction exhibits poor flow behaviour below a D10 of 90 µm when moisture content exceeds 0.6% by USP <731>. A veterinary-grade lot is released only when total related substances are ≤0.5% by Ph. Eur. 2.2.29 and loss on drying is ≤0.5%. The dry-blend formula consists of SDM 500.0 mg, microcrystalline cellulose PH102 96.0 mg, crospovidone 20.0 mg, colloidal silicon dioxide 4.0 mg, and magnesium stearate 2.5 mg per unit. Microcrystalline cellulose is pre-screened through an 850 µm mesh, then blended in a V-blender at 25 rpm for 15 min before magnesium stearate is added for the final 3 min at 18 rpm. Compression is performed on a rotary press with 19.0 × 9.0 mm oval tooling; the press force window is 80–120 MPa. Tablets outside 6.0–10.0 kp hardness are rejected because tensile strength below 1.2 MPa increases edge chipping during coating and tensile strength above 2.0 MPa retards disintegration beyond 15 min. Friability is controlled at ≤1.0% by USP <1216>. Dissolution release uses USP <711> apparatus 2 with 0.1 M HCl at 37 °C and 75 rpm; the release criterion is not less than 75% dissolved at 45 min. Uniformity of dosage units is tested to USP <905>. The main batch-to-batch failure mode during compaction is lamination because fine SDM crystals adhere to the die wall when lubrication is insufficient; when ambient relative humidity exceeds 60% RH, the API is pre-dried at 45 °C for 4 h in a forced-air oven and re-tested before weighing.

Why Does pH Buffering Limit SDM Injectable Stability?

Injectable formulations use the sodium salt because the free acid exhibits aqueous solubility below 1 mg/mL at neutral pH, whereas the sodium salt dissolves readily at pH 10.0–10.5. A 400 mg/mL SDM injectable is prepared in a stainless steel compounding vessel with water for injection at 65–70 °C; the process begins by adding propylene glycol 40% v/v, benzyl alcohol 1.5% v/v, sodium metabisulfite 0.1% w/v, and disodium edetate 0.01% w/v under nitrogen sparge at 0.5 L/min. SDM sodium equivalent to 400 mg/mL of free acid is added in three equal portions, each dissolved for 10 min before the next addition. The pH is adjusted with 0.1 M NaOH to 10.0–10.5; below 9.4 the free acid begins precipitating, and above 10.8 the rate of sulfonamide hydrolysis increases during storage. After cooling to 25 °C, the bulk solution is filtered through a 0.45 µm prefilter and then a 0.22 µm sterilising-grade membrane. Terminal autoclaving at 121 °C for 15 min is used only after thermal stability is confirmed by stress testing; otherwise aseptic filtration is retained. The finished solution is filled into amber ampoules under nitrogen headspace; extractables are assessed according to Ph. Eur. 3.2.2 and visible particulates are checked to USP <790>. Accelerated storage at 40 °C/75% RH for 6 months under a VICH GL3 protocol is required to justify shelf-life, with free-acid precipitation and related substances as the two failure endpoints. The principal incompatibility is contact with acidic vehicle components; citrate or phosphate buffers below pH 8.2 produce immediate precipitation on mixing and are avoided in line-cleaning procedures as well as formulation compounding.

For mass medication in poultry houses through drinking water, 40% w/w SDM sodium soluble powder is dry-blended with lactose monohydrate 57% w/w, anhydrous sodium carbonate 2% w/w, and povidone K30 1% w/w in a double-cone blender at 20 rpm for 20 min. Potency calculations are expressed on the free acid basis, and the sodium salt correction factor is applied at weighing. The sodium carbonate buffer is included to keep reconstituted drinking water above pH 9.0, because water hardness ions and acidic oxidisers reduce solubility. The blend is milled through a 0.8 mm screen and packed into foil-lined bags only after moisture content is confirmed below 0.5% by USP <731>. The reconstitution target is 50 g/L of product in water at 20 °C without agitation; metering pumps deliver the stock solution through a 0.2 mm in-line filter to prevent nozzle blockage. The terminal oral solution is prepared by reconstituting 1 kg of powder per 200 L of drinking water to give a 0.2% w/v SDM stock, subject to veterinary prescription. Turbidity above 10 NTU after 30 min indicates incomplete hydration or excessive hardness; such batches are not released for mass administration. The anti-caking layer must remain hydrophobic because the sodium salt is hygroscopic and clumps above 40% RH. Packaging lines therefore operate at 25 °C and 35% RH with sealing completed within 15 min of filling. Blend uniformity is assessed by sampling 10 locations across the double-cone blender; acceptance is 90–110% of label claim with relative standard deviation ≤5.0% per USP <905>.

Performance loss in pelleted medicated feed when SDM premix exceeds 1200 g/t

Feed premix formulations containing SDM are typically prepared at 10–25% w/w active strength on calcium carbonate or ground rice hull carriers. The primary processing risk is not the initial mixing step but downstream steam conditioning when the premix is diluted to 100–1200 g/t final feed strength. In a horizontal ribbon mixer with working volume 250 kg, the carrier is first blended with 2–3% soybean oil to reduce dusting and electrostatic drift, then SDM is added through a 600 µm screen and mixed for 15 min at 30 rpm. Premix homogeneity is accepted only when ten samples show relative standard deviation ≤5.0% by HPLC with UV detection at 270 nm. For pelleted feed, the conditioner temperature is limited to 70–75 °C with 15–20 s residence time because sulfonamide ring hydrolysis can occur above 80 °C in high-moisture steam. Published data for this specific configuration is limited, so continuous recovery monitoring by extraction and HPLC is required for each pellet mill batch. The terminal pelleted product must be sampled at the cooler discharge, not before post-pellet oil coating, to avoid segregation. Carryover into non-medicated feed is managed by sequencing and purge; a 50 kg flush with ground rice hulls or limestone after each medicated lot is common. The rinsate is assayed and may be used only in the next medicated batch of the same drug. Residual drug on contact surfaces is checked by swab sampling with an acceptance limit derived from 0.1% of the lowest therapeutic dose. Feed use is subject to clearance under 21 CFR Part 558 where applicable, and formulators must verify species and production-class approval before use.

Capsule Fill Parameters for APIs with Static Charge and Low Bulk Density

Filling SDM 250 mg hard gelatin capsules on a dosator-type machine requires control of blend bulk density and electrostatic charge because the API crystal habit produces high interparticulate friction and poor flow. The capsule blend uses SDM 250 mg, pregelatinised maize starch 110 mg, sodium starch glycolate 8 mg, colloidal silicon dioxide 2 mg, and magnesium stearate 3 mg; this produces a fill weight of approximately 373 mg into a size 0 shell. Prior to encapsulation, the blend is passed through a 500 µm screen and rested at 25 °C/40% RH for 4 h to dissipate static charge. Powder flow is measured on a rotational shear cell; a flow function coefficient below 4.0 triggers re-screening and additional colloidal silicon dioxide. During encapsulation, fill weight variation is controlled at ±3.0% and checked every 15 min with a 10-capsule sample. The dissolution test uses USP <711> apparatus 2 in 900 mL of 0.1 M HCl at 75 rpm; a release criterion of not less than 75% dissolved in 45 min is applied. The shells are stored at 15–25 °C and 35–45% RH before filling to prevent brittleness. At room humidity above 50% RH, the blend increases moisture and the sodium starch glycolate swells prematurely; encapsulation is stopped if humidity exceeds 50% RH for more than 30 min.

When Wet Granulation Is Replaced by Roller Compaction for SDM Granules

When roller compaction substitutes for wet granulation, the decision is driven by hydrolytic degradation risk in aqueous binder systems rather than by particle size alone. In high-shear wet granulation, SDM is granulated with povidone K30 5% w/w aqueous solution at impeller speed 300 rpm and chopper 1500 rpm for 3 min, then dried in a fluid-bed system with inlet air at 65 °C until loss on drying is ≤1.0%. The dried granules are passed through a 0.8 mm screen. The aqueous binder initiates partial surface dissolution of SDM; this can reduce polymorphic crystallinity and increase residual moisture. Roller compaction, by contrast, uses vertical feed screw speed 25 rpm, roll pressure 5.0–6.0 MPa, and roll gap 1.0–1.5 mm to form ribbons; the ribbons are milled through a 1.0 mm screen to a granule bulk density 0.55–0.68 g/mL. The granule particle size target is 150–800 µm. Tablets produced from roller-compacted granules show lower residual moisture and higher stability under accelerated storage conditions 40 °C/75% RH; however, compaction pressure above 6.5 MPa can cause work-hardening of the ribbon and reduce tensile strength below 1.0 MPa after final compression. The release of SDM from roller-compacted granules is tested using USP <711>; disintegration time is controlled below 15 min in 900 mL water at 37 °C per USP <701>.

An oral suspension for in-field dilution can be manufactured from the free acid grade if the particle size is reduced to a D90 of ≤30 µm and the suspending system maintains yield stress above 0.5 Pa. The API is micronised using a spiral jet mill with 6.0 bar grinding pressure and 4.5 bar feed pressure; the micronised powder is mixed with xanthan gum 0.2% w/v, microcrystalline cellulose 1.0% w/v, sodium carboxymethylcellulose 0.3% w/v, and citric acid 0.05% w/v to control pH 4.5–5.5. The vehicle includes sorbitol 20% v/v, glycerin 10% v/v, methylparaben 0.1% w/v, and propylparaben 0.02% w/v. The suspension is prepared by dispersing the gums in glycerin before adding water at 70 °C, then cooling and homogenising at 5000 rpm for 10 min. The finished suspension is filled into amber plastic bottles; redispersibility is confirmed by shaking 10 times and then measuring viscosity between 200–400 mPa·s at 25 °C using a rotational viscometer. Particle size of the suspended API is monitored by laser diffraction ISO 13320-1:2020; D90 drift above 35 µm after 6 months at 40 °C/75% RH indicates crystal growth or agglomeration and fails the stability specification. Sedimentation volume after 24 h should be between 0.9 and 1.0. The acid pH in the suspending vehicle keeps the sulfonamide in the free-acid state and reduces bitter taste; however, pH below 4.0 can hydrolyse the sulfonamide bond during long-term storage, and pH above 6.0 can dissolve a portion of the API and alter the dissolution profile. The pH is therefore controlled at 4.5–5.5 and verified by USP <791>.